I have been following RA for years now. There is a small public company (OMX:SYNACT) I found that are in its Phase 2b with a medication that looks very promising. They completed their Phase 2a with statistical significance in a couple of key indicators. It looks like to be on par with JAK inhibitors but with a cleaner safety profile and no need for injections.
Unlike the JAK inhibitors that suppresses the immune system, their pill instead resolves the inflammation by activating receptor 1 and 3 in the melanocortin system. Phase 2b completes this summer and I am personally super excited to see the results.
[1] https://avro.apache.org/
[2] https://parquet.apache.org/